Ligand Pharmaceuticals Incorporated – NASDAQ:LGND
Ligand Pharmaceuticals Incorporated stock price today
$149.05
+39.86
+36.51%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Ligand Pharmaceuticals Incorporated stock price monthly change
+9.84%
month
Ligand Pharmaceuticals Incorporated stock price quarterly change
+9.84%
quarter
Ligand Pharmaceuticals Incorporated stock price yearly change
+51.02%
year
Ligand Pharmaceuticals Incorporated key metrics
Market Cap | 2.15B |
Enterprise value | 1.30M |
P/E | -234.34 |
EV/Sales | 0.01 |
EV/EBITDA | 0.07 |
Price/Sales | 0.01 |
Price/Book | 2.11 |
PEG ratio | 2.05 |
EPS | 5.29 |
Revenue | 118.31M |
EBITDA | 48.12M |
Income | 93.82M |
Revenue Q/Q | -29.56% |
Revenue Y/Y | -45.69% |
Profit margin | -15.75% |
Oper. margin | -9.45% |
Gross margin | 44.31% |
EBIT margin | -9.45% |
EBITDA margin | 40.68% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLigand Pharmaceuticals Incorporated stock price history
Ligand Pharmaceuticals Incorporated stock forecast
Ligand Pharmaceuticals Incorporated financial statements
Average Price Target
$146
Potential downside: -2.04%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 26.36M | 2.29M | 8.69% |
|---|---|---|---|
| Sep 2023 | 32.86M | -12.79M | -38.92% |
| Dec 2023 | 28.10M | 18.18M | 64.72% |
| Mar 2024 | 30.97M | 86.13M | 278.07% |
| Jun 2023 | 758105000 | 93.21M | 12.3% |
|---|---|---|---|
| Sep 2023 | 769210000 | 103.80M | 13.5% |
| Dec 2023 | 833064000 | 130.70M | 15.69% |
| Mar 2024 | 913869000 | 107.34M | 11.75% |
| Jun 2023 | -82K | 7.55M | -67.75M |
|---|---|---|---|
| Sep 2023 | 7.64M | -19.50M | 3.27M |
| Dec 2023 | 8.06M | -10.28M | 5.31M |
| Mar 2024 | 18.69M | -3.77M | 12.22M |
Ligand Pharmaceuticals Incorporated alternative data
| Aug 2023 | 76 |
|---|---|
| Sep 2023 | 76 |
| Oct 2023 | 76 |
| Nov 2023 | 76 |
| Dec 2023 | 76 |
| Jan 2024 | 76 |
| Feb 2024 | 76 |
| Mar 2024 | 58 |
| Apr 2024 | 58 |
| May 2024 | 58 |
| Jun 2024 | 58 |
| Jul 2024 | 58 |
Ligand Pharmaceuticals Incorporated other data
59.53%
-30.33%
of LGND is owned by hedge funds
136
-58
10.01M
-5.48M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 140 |
| Mar 2024 | 0 | 1893 |
| May 2024 | 0 | 41825 |
| Aug 2024 | 2500 | 38603 |
| Sep 2024 | 0 | 19322 |
| Nov 2024 | 0 | 2406 |
| Dec 2024 | 0 | 2104 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ESPINOZA OCTAVIO officer: Chief Financial Officer | Common Stock | 2,104 | $116.37 | $244,851 | ||
Option | LAMATTINA JOHN L director | Common Stock | 2,406 | $52.3 | $125,834 | ||
Sale | LAMATTINA JOHN L director | Common Stock | 2,406 | $123.65 | $297,502 | ||
Option | LAMATTINA JOHN L director | Non-Qualified Stock Option (right to buy) | 2,406 | $52.3 | $125,834 | ||
Option | REARDON ANDREW officer: CLO & Secretary | Employee Stock Option (right to buy) | 2,000 | $52.27 | $104,540 | ||
Option | REARDON ANDREW officer: CLO & Secretary | Common Stock | 2,000 | $52.27 | $104,540 | ||
Sale | REARDON ANDREW officer: CLO & Secretary | Common Stock | 2,000 | $99.6 | $199,202 | ||
Option | KORENBERG MATTHEW E officer: Presiden.. | Common Stock | 9,377 | $52.84 | $495,481 | ||
Sale | KORENBERG MATTHEW E officer: Presiden.. | Common Stock | 2,481 | $100.05 | $248,229 | ||
Option | KORENBERG MATTHEW E officer: Presiden.. | Common Stock | 395 | $49.99 | $19,746 |
| Patent |
|---|
Application Filling date: 16 Apr 2020 Issue date: 30 Jun 2022 |
Application Filling date: 28 Oct 2021 Issue date: 21 Apr 2022 |
Grant Utility: Prodrug compounds and their uses Filling date: 30 Aug 2019 Issue date: 22 Mar 2022 |
Grant Utility: Heterocycle amines and uses thereof Filling date: 7 Jan 2020 Issue date: 30 Nov 2021 |
Application Filling date: 13 Feb 2019 Issue date: 29 Apr 2021 |
Application Filling date: 15 Oct 2020 Issue date: 11 Feb 2021 |
Grant Filling date: 16 Sep 2019 Issue date: 29 Dec 2020 |
Application Filling date: 3 Aug 2020 Issue date: 19 Nov 2020 |
Application Filling date: 8 Jan 2019 Issue date: 29 Oct 2020 |
Grant Filling date: 1 Oct 2018 Issue date: 4 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Agenus: Multiple Milestones In The Second Half Of 2024
Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Viking Therapeutics: Future Weight Loss Heavyweight?
Ligand Pharmaceuticals: A Complicated Tale
Ligand: Nothing Exciting Stands Out
Ligand Pharmaceuticals: The New Ligand Is Looking Good
Ligand Pharmaceuticals: Expanding Royalty Portfolio And Strong Drug Pipeline
OmniAb: Legitimate Competition To AbCellera In Antibody Discovery
-
What's the price of Ligand Pharmaceuticals Incorporated stock today?
One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $149.05.
-
When is Ligand Pharmaceuticals Incorporated's next earnings date?
Unfortunately, Ligand Pharmaceuticals Incorporated's (LGND) next earnings date is currently unknown.
-
Does Ligand Pharmaceuticals Incorporated pay dividends?
No, Ligand Pharmaceuticals Incorporated does not pay dividends.
-
How much money does Ligand Pharmaceuticals Incorporated make?
Ligand Pharmaceuticals Incorporated has a market capitalization of 2.15B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33.09% to 131.31M US dollars.
-
What is Ligand Pharmaceuticals Incorporated's stock symbol?
Ligand Pharmaceuticals Incorporated is traded on the NASDAQ under the ticker symbol "LGND".
-
What is Ligand Pharmaceuticals Incorporated's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ligand Pharmaceuticals Incorporated?
Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ligand Pharmaceuticals Incorporated's key executives?
Ligand Pharmaceuticals Incorporated's management team includes the following people:
- Mr. John L. Higgins Chief Executive Officer & Executive Director(age: 55, pay: $1,180,000)
- Mr. Matthew W. Foehr Pres & Chief Operating Officer(age: 52, pay: $938,810)
- Mr. Matthew E. Korenberg Executive Vice President of Fin. & Chief Financial Officer(age: 50, pay: $754,090)
- Mr. Charles S. Berkman Senior Vice President, Gen. Counsel & Sec.(age: 56, pay: $624,860)
-
How many employees does Ligand Pharmaceuticals Incorporated have?
As Jul 2024, Ligand Pharmaceuticals Incorporated employs 58 workers.
-
When Ligand Pharmaceuticals Incorporated went public?
Ligand Pharmaceuticals Incorporated is publicly traded company for more then 32 years since IPO on 18 Nov 1992.
-
What is Ligand Pharmaceuticals Incorporated's official website?
The official website for Ligand Pharmaceuticals Incorporated is ligand.com.
-
Where are Ligand Pharmaceuticals Incorporated's headquarters?
Ligand Pharmaceuticals Incorporated is headquartered at 5980 Horton Street, EmeryVille, CA.
-
How can i contact Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated's mailing address is 5980 Horton Street, EmeryVille, CA and company can be reached via phone at 858 550 7500.
-
What is Ligand Pharmaceuticals Incorporated stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Ligand Pharmaceuticals Incorporated in the last 12 months, the avarage price target is $146. The average price target represents a -2.04% change from the last price of $149.05.
Ligand Pharmaceuticals Incorporated company profile:
Ligand Pharmaceuticals Incorporated
ligand.comExchange:
NASDAQ
Full time employees:
58
Industry:
Biotechnology
Sector:
Healthcare
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
5980 Horton Street
EmeryVille, CA 94608
EmeryVille, CA 94608
CIK: 0000886163
ISIN: US53220K5048
CUSIP: 53220K504
